HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target

Benzinga · 05/13 10:46
HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price target.